Co-Diagnostics, Inc. Aktie News

SALT LAKE CITY , Nov. 20, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company's Executive Vice President of Business Development, Joseph Featherstone, addressed a satellite session of the International Union Against...

SALT LAKE CITY , Nov. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has begun clinical evaluations for its Co-Dx™ PCR Flu A/B, COVID-19, RSV Test Kit. The clinical performance testing is expected to support a submi...

Co-Diagnostics, Inc. ( CODX ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chairman & CEO Brian Brown - CFO & Company Secretary Conference Call Participants Michael Okunewitch - Maxim Group LLC, Research Division Presentation Operator Hello, and thank you for standing by. My name is Tiffany, and I will be your ...

SALT LAKE CITY , Nov. 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Business Highlights: Performed in-silico analy...

Co-Diagnostics, Inc. ( CODX ) Discusses Saudi Arabia Joint Venture, AI Initiatives and Diagnostics Technology Developments November 5, 2025 11:00 AM EST Company Participants Dwight Egan - Chairman & CEO Conference Call Participants Valter Pinto Presentation Valter Pinto Good morning, and welcome, everyone, to the Co-Diagnostics fireside chat. My name is Valter Pinto.

SALT LAKE CITY , Nov. 5, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a patented platform for developing advanced molecular diagnostic tests, today announced that it has engaged Maxim Group LLC ("Maxim") as its exclusive financial advisor to assist the Company in identifying potential strategic alternatives for the Com...

Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx's existing and future AI initiatives SALT LAKE CITY , Nov. 3, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announ...

SALT LAKE CITY , Oct. 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2025 financial results on Thursday, November 13, 2025, after the market close. The Company will also host a conference call and webcast on the same...